


*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



MAY 23 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 12

<i>Complete If Known</i>	
Application Number	09/832,648
Filing Date	April 11, 2001
First Named Inventor	Cy A. Stein et al.
Art Unit	1635
Examiner Name	J. Epps-Ford
Attorney Docket Number	0575/55669-Z

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered


10-7-05

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Applicant: Cy A. Stein et al.
U.S. Serial No.: 09/832,648
Filed: May 31, 2002
Exhibit A**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08B (08-03)

Substitute for form 1449 PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	09/832,648
Filing Date	April 11, 2001
First Named Inventor	Cy A. Stein
Art Unit	1635
Examiner Name	J. Epps-Ford
Attorney Docket Number	0575/55669-Z

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>je</i>	1	Supplementary European Search Report issued March 1, 2005 in connection with European Application No. 99933713.2	
<i>je</i>	2	Amarente-Mendes, G.P. et al. (1998), "Bcl-2 Independent BCR-ABL-mediated Resistance to Apoptosis: Protection is Correlated with Up-Regulation of Bcl-XL" Oncogene, 16:1383-1390	
<i>je</i>	4	Leech G.H. et al. (1998), "Antisense Oligodeoxynucleotides Designed to Downregulate the Expression of Bcl-XL and of Bcl-XL." Proc. Ann. Meet. Am. Assoc. Canc. Res. NY, 39:417	
	5	Luedke G.H. et al. (1997), "Antisense Oligonucleotides Targeting Sequences Shared by the Bcl-2 and the Bcl-XL mRNA..." Proc. Ann. Meet. Am. Assoc. Canc. Res. NY, 38:A1140	
	6	Crooke S.T. (1998), "Basic principles of Antisense Therapeutics" Antisense research and Applications, CRC Press, pages 1-50	
<i>je</i>	7	WO 95/08350 A, Reed J., published March 30, 1995 Duplicate of ref #7 IDS page #1	

Examiner Signature	<i>Jeff Epps Ford</i>	Date Considered	10-2-05
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.